BLU Stock Overview
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications.
BELLUS Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$15.15|
|52 Week High||CA$16.24|
|52 Week Low||CA$3.69|
|1 Month Change||20.53%|
|3 Month Change||48.24%|
|1 Year Change||288.46%|
|3 Year Change||64.39%|
|5 Year Change||1,022.22%|
|Change since IPO||-98.41%|
Recent News & Updates
We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, BELLUS Health ( TSE:BLU...
|BLU||CA Biotechs||CA Market|
Return vs Industry: BLU exceeded the Canadian Biotechs industry which returned 7.9% over the past year.
Return vs Market: BLU exceeded the Canadian Market which returned -2% over the past year.
|BLU Average Weekly Movement||11.3%|
|Biotechs Industry Average Movement||12.9%|
|Market Average Movement||10.8%|
|10% most volatile stocks in CA Market||19.4%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: BLU is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BLU's weekly volatility (11%) has been stable over the past year.
About the Company
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
BELLUS Health Fundamentals Summary
|BLU fundamental statistics|
Is BLU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLU income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.56|
|Net Profit Margin||-436,406.25%|
How did BLU perform over the long term?See historical performance and comparison
Is BLU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLU?
Other financial metrics that can be useful for relative valuation.
|What is BLU's n/a Ratio?|
Price to Book Ratio vs Peers
How does BLU's PB Ratio compare to its peers?
|BLU PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
EDT Spectral Medical
BCT BriaCell Therapeutics
MDNA Medicenna Therapeutics
BLU BELLUS Health
Price-To-Book vs Peers: BLU is good value based on its Price-To-Book Ratio (5.3x) compared to the peer average (21.7x).
Price to Earnings Ratio vs Industry
How does BLU's PE Ratio compare vs other companies in the CA Biotechs Industry?
Price-To-Book vs Industry: BLU is expensive based on its Price-To-Book Ratio (5.3x) compared to the Canadian Biotechs industry average (3x)
Price to Book Ratio vs Fair Ratio
What is BLU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||5.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate BLU's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BLU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BLU (CA$15.15) is trading above our estimate of fair value (CA$5.39)
Significantly Below Fair Value: BLU is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is BELLUS Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLU's revenue (82.6% per year) is forecast to grow faster than the Canadian market (6.3% per year).
High Growth Revenue: BLU's revenue (82.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLU's Return on Equity is forecast to be low in 3 years time (16.7%).
Discover growth companies
How has BELLUS Health performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLU is currently unprofitable.
Growing Profit Margin: BLU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLU is unprofitable, and losses have increased over the past 5 years at a rate of 58.5% per year.
Accelerating Growth: Unable to compare BLU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (47.6%).
Return on Equity
High ROE: BLU has a negative Return on Equity (-24.96%), as it is currently unprofitable.
Discover strong past performing companies
How is BELLUS Health's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BLU's short term assets ($245.0M) exceed its short term liabilities ($16.0M).
Long Term Liabilities: BLU's short term assets ($245.0M) exceed its long term liabilities ($554.0K).
Debt to Equity History and Analysis
Debt Level: BLU is debt free.
Reducing Debt: BLU has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLU has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BLU has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 50.1% each year.
Discover healthy companies
What is BELLUS Health current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BLU has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roberto Bellini (42 yo)
Mr. Roberto Francesco Bellini has been the Chief Executive Officer and President of BELLUS Health Inc, since January 1, 2010. Mr. Bellini served as an Executive Vice President of Picchio Pharma Inc. until...
CEO Compensation Analysis
Compensation vs Market: Roberto's total compensation ($USD1.78M) is about average for companies of similar size in the Canadian market ($USD2.30M).
Compensation vs Earnings: Roberto's compensation has been consistent with company performance over the past year.
Experienced Management: BLU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: BLU's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.6%.
BELLUS Health Inc.'s employee growth, exchange listings and data sources
- Name: BELLUS Health Inc.
- Ticker: BLU
- Exchange: TSX
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$1.906b
- Shares outstanding: 125.79m
- Website: https://www.bellushealth.com
Number of Employees
- BELLUS Health Inc.
- 275 Armand-Frappier Boulevard
- H7V 4A7
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.